Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK239512 in mild to moderate Alzheimer's disease
2009-012614-48Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing GSK239512 with Placebo (2 arms). Primary endpoint: Change from baseline in executive function/working memory composite score (CogState). Started Jul 2009; status: completed.
02
Drugs
gsk239512
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-012614-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012614-48.